This site is intended for health professionals only
Monday 29 May 2017
Share |

Merck initiates Phase III study of MSB11022 in chronic plaque psoriasis

Merck, a leading science and technology company, announced the initiation of a global Phase III clinical study of MSB11022, a proposed biosimilar of adalimumab, in chronic plaque psoriasis. This milestone is a strong reflection of Merck’s progress in biosimilars, with the goal of delivering high-quality biologics to patients all over the world.
 

Ads by Google